Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy

International Journal of Cancer

Volumn 99, Issue 1, 2002, Pages 1-6

  Siemann, Dietmar W ^a   Mercer, Emma ^a   Lepler, Sharon ^a   Rojiani, Amyn M ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Antivascular therapies; CA4DP; Cisplatin; Cyclophosphamide; DMXAA

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANTINEOPLASTIC AGENT; CISPLATIN; COMBRETASTATIN A4; COMBRETASTATIN A4 PHOSPHATE; CYCLOPHOSPHAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER MODEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; EVALUATION; FEMALE; HISTOLOGY; ISCHEMIA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SOLID TUMOR; TUMOR NECROSIS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD VESSELS; CISPLATIN; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICE, INBRED C3H; MICE, NUDE; NECROSIS; NEOVASCULARIZATION, PATHOLOGIC; SARCOMA, EXPERIMENTAL; STILBENES; TUMOR CELLS, CULTURED; XANTHENES; XANTHONES;

EID: 0036568457     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10316     Document Type: Article

References (36)

1. Tumor angiogenesis
2. The current status of targeting tumour vasculature as a means of cancer therapy-an overview
3. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid
4. Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids
5. Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice
6. Preclinical in vitro and in vivo activity of 5,6- dimethylxanthenone-4- acetic acid
7. Induction of tumor necrosis factor, a messenger RNA in human and murine cells, by the flavone acetic analogue 5,6, dimethylxanthenone-4-acetid acid(NSC64088)
8. Induction of tumour necrosis factor α by single and repeated doses of the antitumor agent 5,6dimethylxanthenone-4-acetic acid
9. Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown
10. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature
11. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: Effects on radiation therapy
12. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
13. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues
14. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate
15. Targeting tumor blood vessels: An adjuvant strategy for radiation therapy
16. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo
17. Interaction between combretastatin A4 disodium phosphate and radiation in murine tumours
18. Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS- associated Kaposi's sarcoma
19. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumours
20. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs
21. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid
22. Improved tumor response by combining radiation and the vascular damaging drug 5,6-dimethylxanthenone-4-acetic acid
23. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flowmodifying agents
24. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-bloodflow inhibitor 5,6-dimethylxanthenone-4-acetic acid
25. Enhancement of antibodydirected enzyme prodrug therapy in colorectal xenografts by an antivascular agent
26. Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma
27. Combination chemotherapy with combretastatin A-4 phosphate and 5 fluorouracil in an experimental murine colon adenocarcinoma
28. Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma
29. Potentiation of cisplatin activity by the bioreductive agent tirapazamine
30. Prediction of tumour sensitivity to 4-hydroperoxycyclophosphamide by a glutathione-targeted assay
31. Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours
32. Area and volume measurements by random sampling methods
33. Recovery of cell subpopulations from human tumour xenografts following dissociation with different enzymes
34. Chemosensitization of CCNU in KHT murine tumor cells in vivo and in vitro by the agent RB 6145 and its isomer PD 144872
35. Potentiation of combination chemotherapy by nitroheterocyclics
36. Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity